Skip to main content
31 May. 2021

Post-market Review of Opiate Dependence Treatment Program (ODTP) Medicines Public Consultation

Please see advice below from the Opiate Dependence Treatment Program Australian Government Department of Health:

On 24 March 2021 it was announced the Department of Health will conduct a post-market review of the medicines listed on the Pharmaceutical Benefits Scheme (PBS) Opiate Dependence Treatment Program (the ODTP PMR).  The ODTP PMR is an opportunity to review the current program arrangements to ensure that Australians who have an opioid dependency continue to have access to medicines to help treat their opioid dependence. The ODTP PMR will examine important issues such as barriers to access and the future delivery of opioid dependence treatment.

This ODTP PMR will follow the Post-market Review Framework, which includes public consultation on the draft Terms of Reference, an opportunity to provide submissions to the review, and an opportunity to comment on the draft review report.

There are currently three medicines available for the treatment of opioid dependence under the PBS ODTP. Medicines to be included in the ODTP PMR are buprenorphine (tablets and modified release injections), buprenorphine with naloxone (films) and methadone (oral liquid).

Public consultation on the draft Terms of Reference for the ODTP PMR is now open and will close at 23:30 AEST on Wednesday, 30 June 2021.  Further information on the ODTP PMR, including the process for providing comments on the draft Terms of Reference, is available on the PBS Reviews website.

For PBS news updates and the latest information on post-market reviews, including public consultation processes and publication of review reports, please subscribe to the PBS email list. For any queries, please contact the ODTP PMR secretariat

Kind regards,

Opiate Dependence Treatment Program

Australian Government Department of Health